Monday, September 03, 2007

Aluminum In Breast Tissue: A Possible Factor In The Cause Of Breast Cancer

A new study has identified a regionally-specific distribution of aluminium in breast tissue which may have implications for the cause of breast cancer. Scientists have found that the aluminium content of breast tissue and breast tissue fat was significantly higher in the outer regions of the breast, in close proximity to the area where there would be the highest density of antiperspirant. Recent research has linked breast cancer with the use of aluminium-based, underarm antiperspirants. The known, but unaccounted for, higher incidence of tumours in the upper outer quadrant of the breast seemed to support such a contention. However, the identification of a mechanism of antiperspirant-induced breast cancer has remained elusive. --Click the title of this post to read the full article from its source--

Labels: , , , ,

Sunday, September 02, 2007

Breastfeeding Decreases Possibilities of Having Breast Cancer

Breastfeeding is not only necessary for newborns to be nurtured, it also plays a role in reducing the chances of getting breast cancer. According to the Sprecher Institute for Comparative Cancer Research in New York, breastfeeding reduces the risk of having breast cancer 10 percent to 64 percent compared to women who don’t breastfeed. Statistics may vary depending on the pattern of breastfeeding, how often the baby is fed and the reasons for stopping it afterward. “There is no clear scientific explanation for that, although the information is correct according to studies. Breastfeeding decreases the possibility of having the disease,” said Dr. Mahmoud Al-Ahwal, consultant and associate professor of internal medicine and medical oncology at King Abdul Aziz University Hospital and a member of Al-Eman Cancer Society’s executive committee. “While breastfeeding, breast cells are doing the natural job that God created them for,” he said. --Click the title of this post to read the full article from its source--

Labels: , ,

Saturday, March 03, 2007

US drug firm to pay $3m in cancer suit

A Pennsylvania jury awarded $3 million on Tuesday to an Ohio woman who claimed a hormone replacement drug made by Wyeth had caused her breast cancer. The woman, Jennie Nelson, 67, of Dayton, was found to have breast cancer in 2001 after taking the drug, prempro, for five years to treat symptoms of menopause. Her lawyers said Wyeth knew for decades the drug could cause breast cancer but had failed to warn patients. More than 5,000 women have sued Wyeth over its hormone drugs Premarin and Prempro. Wyeth has won two cases and lost two cases, which have been heard in Arkansas and Philadelphia. --Click the title of this post to read the full article from its source--

Labels: , , , , , ,

Saturday, December 23, 2006

Tamoxifen Has Late Effect in Preventing Breast Cancer

Tamoxifen is associated with a highly significant reduction in the incidence of estrogen receptor-positive invasive breast cancer that predominantly occurs after the 8-year treatment period, according to long-term follow-up results from the Royal Marsden Tamoxifen Breast Cancer Prevention Trial."This late effect indicates a preventative rather than a treatment effect on established occult disease," said Trevor J. Powles, MD, emeritus professor of breast oncology, Institute of Cancer Research, and lead clinician, Parkside Oncology Centre, London, United Kingdom. --Click the title of this post to read the full article from its source--

Labels: , , , , ,

Monday, December 18, 2006

New Study Shows Efficacy Of AROMASIN On Early Breast Cancer

New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56% less likely to have a relapse of breast cancer than those who received placebo (P=0.004).“Aromasin provided patients with improved relapse-free survival despite early study closure, unblinding and crossover in the placebo arm,” said Dr. Terry Mamounas, NSABP breast committee chairman and lead investigator for the B-33 study. Median follow-up of 30 months also showed that disease-free survival was improved by 32% (P=0.07). Toxicity experienced with Aromasin in the B-33 trial was acceptable for the adjuvant setting. --Click the title of this post to read the full article from its source--

Labels: , , , , , , ,

Young breast cancer patients test super-hormone treatment

Young women are getting a shot of a male hormone testosterone often used to treat prostate cancer as part of a super-hormone treatment that new research suggests may improve their survival odds for breast cancer. This chemical equivalent of ovary removal has one big advantage over surgery: it's not permanent, so it may preserve a woman's ability to have children. In premenopausal women, the drugs suppress the pituitary gland, which produces hormones that control the ovaries and cause a woman to have a period every month. Side effects of this induced early menopause are similar to those of natural menopause _ hot flashes, night sweats, etc., according to new research presented at the San Antonio Breast Cancer Symposium, which ended Sunday. The drugs are most often used in two situations:
  • As an alternative to chemotherapy for women who have had surgery for small, hormone-fueled tumors and are considered at relatively low risk for recurrence.
  • As a way to keep the ovaries suppressed in women whose periods return after temporarily stopping during chemotherapy.

--Click the title of this post to read the full article from its source--

Labels: , , , ,

Saturday, December 16, 2006

HER2 Vaccine May Reduce Breast Cancer Recurrence

According to results recently presented at the 2006 annual San Antonio Breast Cancer Symposium (SABCS), an experimental HER2 vaccine may reduce the risk of cancer recurrence in some women with high-risk early breast cancer. Although cure rates remain high for patients with early breast cancer, particularly women with node-negative breast cancer, some of these women will experience a cancer recurrence and may ultimately succumb to their disease. Therefore, a reduction in the risk of recurrence among high-risk women is warranted. HER2 is a protein that is overexpressed in twenty to thirty percent of breast cancers. Using a part of the HER2 protein (the E75 peptide), researchers have developed an experimental anticancer vaccine. --Click the title of this post to read the full article from its source--

Labels: , , ,

Friday, December 15, 2006

Research Indicates Breast Cancer Cells May Be Fought With Vitamin E Precursor

Medical data indicates that approximately 30 percent of breast cancers have high levels of a HER2, a human epidermal growth factor receptor. Research conducted by Griffith University's School of Medicine has found that these breast cancer cells may be fought with a precursor of vitamin E. The HER2 feature found in this types of cancer is resistant to many treatments such as chemotherapy. The experimental research study was done on mice. Results show that pro-vitamin E or alpha-tocopheryl succinate (alpha-TOS) can reduce the number of these tumors. --Click the title of this post to read the full article from its source--

Labels: ,

Wednesday, December 13, 2006

Boffins develop antibody that inhibits breast cancer spread in mice

Boffins at the University of Buffalo have come a step further in the fight against breast cancer, by developing a monoclonal antibody that has been able to significantly extend the survival of mice with human breast-cancer tumours, and inhibit the cancer's spread to the their lungs by more than 50 percent. Named JAA-F11, the antibody targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. The researchers noted that while the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to stick to organ tissue. --Click the title of this post to read the full article from its source--

Labels: , ,

Friday, December 01, 2006

Researcher, Pro-Life Advocates React to Abortion Drug-Breast Cancer Study

A leading biochemist who has published internationally-respected studies on breast cancer and a top pro-life organization both reacted to a study released Thursday showing the RU 486 abortion drug helped suppress the breast cancer gene in mice. They agreed the drug will not likely benefit humans. The University of California study showed that the RU 486 abortion drug works to suppress the progesterone hormone that triggers the breast cancer gene to produce cancerous tumors. But Dr. Joel Brind, a Yale-educated endocrinologist who teaches biology at Baruch College in New York, told he doesn't think the drug will offer any benefit to women. "There is reason to believe that RU 486 as an anti-progestin might suppress growth of breast cancer in an experimental system in rodents, but RU 486 also neutralizes the essential hormone cortisol which mice do not make," Brind said. "Therefore, there is good reason to believe that such a drug would not be an effective anti-cancer drug in people," he told --Click the title of this post to read the full article from its source--

Labels: , , , ,

Study: Abortion pill blocks breast cancer gene

American scientists caution that their research is still in the exploratory stages, but recent results have shown the abortion drug RU-486 prevented tumors in mice bred with a breast cancer gene. Although no one is suggesting women use the abortion pill to prevent breast cancer, the experiment did show that RU-486 blocks a hormone called progesterone, which activates the breast cancer gene BRCA1. "All of us have to be cautious," said cell biologist Eva Lee of the University of California, Irvine, who led the research published in Friday's edition of the journal Science. "But I do think if there is a better anti-progesterone available, hopefully there will be other options in the future for these women." Women today have few options to prevent breast cancer, and if researchers could produce a safer hormone blocker it would offer a viable alternative for women with the BRCA1 gene.Cancer specialists not involved with the experiment praised the work, even as they warned women not to get their hopes up. --Click the title of this post to read the full article from its source--

Labels: , , , ,

/* WebRing Code */